Related Experiment Video
Updated: Jul 9, 2025

Multiple Intravenous Bolus Dosing and Invasive Hemodynamic Assessment in a Hypoxia-Induced Mouse Pulmonary Artery Hypertension Model
Published on: November 11, 2022
Pde5 Inhibition Reduced Blood Pressure and Alleviated Target Organ Damage in Chronic Intermittent Hypoxia
Siyi Li1,2, Qingjie Xin1,2, Yan Yan1,2
1Center for Coronary Artery Disease, Division of Cardiology, Beijing Anzhen Hospital, Capital Medical University, Beijing, China; and.
Abstract:
The role of phosphodiesterase 5 (Pde5) in obstructive sleep apnea-induced damage remains unclear. Our study aimed to investigate the role of Pde5 in the chronic intermittent hypoxia (CIH) model. C57BL/6J wild-type (WT) mice (n = 48) and Pde5 knockout (Pde5 -/- ) mice (n = 24) were randomly assigned to CIH group and room air group. After 6 weeks, some WT mice (n = 24) in CIH group were given sildenafil or saline gavage for another 4 weeks. Blood pressure was regularly measured during the experiment. Echocardiography was used to estimate cardiac function. We collected organs from each group of mice and measured their physical indicators. Histochemical staining was used to explore the size of cardiomyocyte and fibrosis area of various organs. Cyclic guanosine monophosphate and malondialdehyde concentrations in serum were measured by ELISA assay. Compared with the RA-treated group, the 6-week CIH resulted in a significant increase in blood pressure, altered heart structure, and reduced serum cyclic guanosine monophosphate in WT mice. Pde5 -/- mice and sildenafil intragastric administration significantly reduced systolic blood pressure in CIH condition and attenuated the damage of target organs. In CIH model, we found that the cardiomyocyte size and fibrosis area of heart and kidney significantly reduced in Pde5 -/- groups. Besides, endogenous and exogenous inhibition of Pde5 reduced malondialdehyde level and inflammatory and oxidative stress markers expression in CIH condition. In this study, we found that Pde5 inhibition could reduce blood pressure and alleviate target organ damage in the CIH model, which may be mediated through the oxidative stress pathway.
Insights
Phosphodiesterase 5 (Pde5) inhibition reduces blood pressure and protects organs from damage caused by chronic intermittent hypoxia (CIH). This suggests Pde5 plays a key role in CIH-induced injury, potentially via oxidative stress pathways.
Area of Science:
- Cardiovascular Research
- Sleep Medicine
- Pharmacology
Background:
- Obstructive sleep apnea (OSA) is linked to cardiovascular complications.
- The role of phosphodiesterase 5 (Pde5) in OSA-induced organ damage is not well understood.
- Chronic intermittent hypoxia (CIH) is a key feature of OSA.
Purpose of the Study:
- To investigate the role of Pde5 in a mouse model of CIH.
- To determine if Pde5 inhibition mitigates CIH-induced damage.
Main Methods:
- Utilized C57BL/6J wild-type (WT) and Pde5 knockout (Pde5-/-) mice exposed to CIH or room air (RA).
- Administered sildenafil (a Pde5 inhibitor) or saline to WT mice under CIH.
- Assessed blood pressure, cardiac function (echocardiography), organ physical indicators, histopathology (cardiomyocyte size, fibrosis), and serum markers (cGMP, MDA).
Main Results:
- CIH increased blood pressure, altered heart structure, and decreased cGMP in WT mice.
- Pde5-/- mice and sildenafil treatment reduced systolic blood pressure and attenuated target organ damage (heart, kidney) in CIH.
- Pde5 inhibition decreased malondialdehyde levels and markers of inflammation and oxidative stress.
Conclusions:
- Pde5 inhibition effectively reduces blood pressure and alleviates target organ damage in a CIH model.
- The protective effects of Pde5 inhibition in CIH may be mediated through the modulation of oxidative stress.
- Targeting Pde5 represents a potential therapeutic strategy for managing CIH-related complications.
Related Concept Videos
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
Pulmonary Hypertension: Classification and Pathogenesis
There are various classifications for PH, each relating to different underlying causes and also...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
Antihypertensive Drugs: Vasodilators
Hypoxia
Types of Hypoxia
There are four primary types of hypoxia, each resulting from a different cause:
1. Anemic hypoxia: This type occurs due to insufficient oxygen delivery caused by a lack of red blood cells (RBCs) or RBCs with abnormal or...

